RxDoctor Payments Data

Paul Saloky, DO

Hospitalist · Bloomsburg, PANPI 1639168149

Payments from drug & device makers

$779in general payments, 2019–2025

Across 28 payments — averaging $27.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$203
  • E.r. Squibb & Sons, L.L.C.$138
  • Molnlycke Health Care US, LLC$132
  • AbbVie$106
  • Johnson & Johnson$49
  • Medline Industries LP$32
  • plus $119 from 6 others

What the payments were for

  • Food & beverage$779100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$779 in reported general payments places this provider in the 85th percentile of 1,287 hospitalist providers in Pennsylvania.

See all hospitalist providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$207,327
Medicare patients
507
Services billed
1,770

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban80$69,280
JardianceEmpagliflozin63$47,406
EntrestoSacubitril/Valsartan30$29,775
FarxigaDapagliflozin Propanediol31$22,732
XareltoRivaroxaban36$19,974
TradjentaLinagliptin23$17,727
Fluticasone-SalmeterolFluticasone Propion/Salmeterol27$3,564
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,246
Metoprolol Succinate75$1,233
Potassium Chloride42$1,115
Valsartan22$952
Torsemide55$736
Amiodarone Hcl42$642
Losartan Potassium60$549
Amlodipine Besylate51$501

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$21$69,28080 claims
Boehringer IngelheimJardiance, Tradjenta$29$65,13386 claims
AstraZenecaFarxiga$14$22,73231 claims
Johnson & JohnsonXarelto$49$19,97436 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,287 hospitalist providers in Pennsylvania.

Other hospitalist in Bloomsburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →